Dr. Sonpavde on Anticipated Data in Bladder Cancer

Guru Sonpavde, MD

Partner | Cancer Centers | <b>Dana Farber</b>

Guru P. Sonpavde, MD, discusses anticipated data in bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses anticipated data in bladder cancer.

Although a lot of data were presented during the 2021 Genitourinary Cancers Symposium, the field of bladder cancer is awaiting results from several key studies, says Sonpavde. For example, more mature survival data from the CheckMate 274 trial (NCT02632409) are anticipated, Sonpavde says. It is known that the trial met its primary end point of improved disease-free survival, so additional findings could be paradigm changing for patients with PD-L1–high bladder cancer.

In the frontline setting, data from the EV-302 study (NCT04223856) with enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) are anticipated.

Moreover, the ongoing CheckMate 901 study (NCT03036098) is comparing nivolumab (Opdivo) plus ipilimumab (Yervoy) with standard of care chemotherapy in patients with untreated, inoperable or metastatic urothelial carcinoma. Patients will be evaluated ​for efficacy based on PD-L1 positivity and cisplatin eligibility, Sonpavde adds. In the cisplatin-eligible population, chemotherapy plus nivolumab vs chemotherapy alone will be evaluated, Sonpavde says.

Other anticipated longer-term survival data include those from the IMvigor130 trial (NCT02807636), which initially demonstrated a modest progression-free survival benefit with atezolizumab (Tecentriq) plus chemotherapy in patients with metastatic urothelial carcinoma, concludes Sonpavde.